Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent
A post hoc subanalysis of the pooled E- and C-SIRIUS trials
Michael Schlüter, PhD*,
Joachim Schofer, MD*,*,
Anthony H. Gershlick, MD
,
Erick Schampaert, MD
,
William Wijns, MD
,
Günter Breithardt, MD, FACC|| for the E- and C-SIRIUS Investigators
* Center for Cardiology and Vascular Intervention, Hamburg, Germany
Glenfield Hospital, Leicester, United Kingdom
Hôpital du Sacré-Coeur de Montréal, Montréal, Canada
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
|| Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany

View larger version (16K):
[in a new window]
|
Figure 1 Mean eight-month late loss at the proximal (Prox.) stent margin, within the stent, and at the distal (Dist.) stent margin. Open bars = predilated lesions; solid bars = directly stented lesions.
|
|

View larger version (12K):
[in a new window]
|
Figure 2 Rates of major adverse cardiac events (MACE) and target lesion revascularization (TLR) at one year. Both clinical outcome variables are markedly, although non-significantly, reduced in patients who underwent DS (solid bars). Open bars = predilation.
|
|
Copyright © 2005 by the American College of Cardiology Foundation.